Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease
Table 2
Statistics for all compounds. Clear lines represent prevention studies and bold represent intervention studies.
Compound
Weight change
Fecal score
WBC count
Colonic weight:length
Histological score
Anti-TNFα
<0.001
<0.001
<0.001
<0.001
<0.0001
<0.05
ns
ns
ns
ns
TNFR-Fc†
<0.01
ns
ns
ns
—
ns
ns
ns
ns
—
Anti-IL-12p40
<0.001
ns
<0.05
<0.001
<0.001
<0.0001
ns
0.001
<0.01
<0.05
Anti-IL-6
<0.01
<0.01
ns
<0.05
<0.05
ns
ns
ns
ns
ns
CTLA4-Ig
<0.01
<0.01
<0.01
<0.001
<0.05*
<0.01
<0.01
<0.001
<0.001
<0.001
Anti-α4β7
<0.0001
<0.01
ns
<0.01
<0.01
ns
ns
ns
ns
ns
Enro + Metro
ns
<0.001
<0.05
<0.001
<0.001
<0.01
<0.001
<0.001
<0.0001
<0.001
Cyclosporine
ns
ns
<0.05**
ns
ns
—
—
—
—
—
†Prevention = 50 mg/kg, intervention = 5 mg/kg.
*Used Wilcoxon signed rank test and compared with a hypothetical value of 0.0 since all scores were 0 in the CTLA4-Ig group.
**WBC count higher in treatment group—not analyzed.
